202 related articles for article (PubMed ID: 2035258)
21. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma.
Eljarmak D; Lis M; Cantin M; Carrière PD; Collu R
Horm Res; 1985; 21(3):160-7. PubMed ID: 3997065
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.
Shimatsu A; Murabe H; Nakamura Y; Mizuta H; Ihara C; Nakao K
Endocr J; 1999 Feb; 46(1):159-65. PubMed ID: 10426581
[TBL] [Abstract][Full Text] [Related]
23. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Jones TH; Figueroa CD; Smith CM; Bhoola KD
Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
[TBL] [Abstract][Full Text] [Related]
24. Effects of bromocriptine on hormone production and cell growth in cultured rat pituitary cells.
Johansen PW; Haug E; Gautvik KM
Acta Endocrinol (Copenh); 1985 Oct; 110(2):200-6. PubMed ID: 4060970
[TBL] [Abstract][Full Text] [Related]
25. Bromocriptine-induced changes in hormone secretion and cell morphology in growth hormone and prolactin producing pituitary adenomas.
Anniko M; Werner S; Wersäll J
Acta Otolaryngol; 1981; 92(3-4):343-55. PubMed ID: 7324902
[No Abstract] [Full Text] [Related]
26. Pituitary tumorigenesis in prolactin gene-disrupted mice.
Cruz-Soto ME; Scheiber MD; Gregerson KA; Boivin GP; Horseman ND
Endocrinology; 2002 Nov; 143(11):4429-36. PubMed ID: 12399440
[TBL] [Abstract][Full Text] [Related]
27. Effect of vasoactive intestinal polypeptide (VIP) on growth hormone (GH) and prolactin (PRL) release and cell morphology in human pituitary adenoma cell cultures.
Fazekas I; Bácsy E; Varga I; Slowik F; Bálint K; Pásztor E; Czirják S; Gláz E
Folia Histochem Cytobiol; 2000; 38(3):119-27. PubMed ID: 10970071
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
29. A case of pituitary somatotroph adenoma with concomitant secretion of growth hormone, prolactin, and adrenocorticotropic hormone--an adenoma derived from primordial stem cell, studied by immunohistochemistry, in situ hybridization, and cell culture.
Matsuno A; Sasaki T; Mochizuki T; Fujimaki T; Sanno N; Osamura Y; Teramoto A; Kirino T
Acta Neurochir (Wien); 1996; 138(8):1002-7. PubMed ID: 8890999
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of action and tolerance of mesulergine.
Lamberts SW; Klÿn JG; Oosterom R
Clin Pharmacol Ther; 1984 Nov; 36(5):620-7. PubMed ID: 6488683
[TBL] [Abstract][Full Text] [Related]
31. Peanut agglutinin binding to human prolactin-producing pituitary adenomas.
Kurosaki M; Hori T; Takata K; Kawakami H; Hirano H
Acta Neuropathol; 1995; 89(6):475-82. PubMed ID: 7676803
[TBL] [Abstract][Full Text] [Related]
32. Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists.
Hamester U; Saeger W; Lüdecke DK
Histol Histopathol; 1987 Apr; 2(2):135-42. PubMed ID: 2980713
[TBL] [Abstract][Full Text] [Related]
33. Ultrastructural localization of prolactin in the human pituitary prolactinomas and its changes by bromocriptine treatment.
Osamura RY; Teramoto A; Watanabe K
Acta Pathol Jpn; 1986 Aug; 36(8):1123-30. PubMed ID: 3776529
[TBL] [Abstract][Full Text] [Related]
34. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study.
Tindall GT; Kovacs K; Horvath E; Thorner MO
J Clin Endocrinol Metab; 1982 Dec; 55(6):1178-83. PubMed ID: 6752167
[No Abstract] [Full Text] [Related]
35. Immunoelectron microscopic observation of prolactin (PRL) in human PRL secreting pituitary adenomas and non-neoplastic pituitary PRL cells.
Osamura RY
Pathol Res Pract; 1988 Sep; 183(5):584-6. PubMed ID: 3070508
[TBL] [Abstract][Full Text] [Related]
36. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study.
Bassetti M; Spada A; Pezzo G; Giannattasio G
J Clin Endocrinol Metab; 1984 Feb; 58(2):268-73. PubMed ID: 6693536
[TBL] [Abstract][Full Text] [Related]
37. Glycoprotein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: correlation with GH release.
Hofland LJ; van Koetsveld PM; Verleun TM; Lamberts SW
Clin Endocrinol (Oxf); 1989 Jun; 30(6):601-11. PubMed ID: 2512040
[TBL] [Abstract][Full Text] [Related]
38. Morphological changes in bromocriptine-treated pituitary tumours.
Anniko M; Wersäll J
Acta Otolaryngol; 1983; 96(3-4):337-53. PubMed ID: 6637451
[TBL] [Abstract][Full Text] [Related]
39. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
Li Q; Su Z; Liu J; Cai L; Lu J; Lin S; Xiong Z; Li W; Zheng W; Wu J; Zhuge Q; Wu Z
Mol Cell Endocrinol; 2014 Jan; 382(1):377-384. PubMed ID: 24184771
[TBL] [Abstract][Full Text] [Related]
40. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
